Stocks Health care ARTV
NASDAQ · Health careArtiva Biotherapeutics, Inc. (ARTV)
It posted a net loss of $98.1M. In fiscal 2025 capital spending exceeded operating cash flow by $79.3M. At September 30, 2026 it held $61.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Artiva Biotherapeutics, Inc.
- Net worth
- Artiva Biotherapeutics, Inc. has a market value (market cap) of $198.5M at the latest share price, and shareholders' equity of $320.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $83.9M.
- Cash flow
- In fiscal 2025 operations used $76.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Artiva Biotherapeutics, Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Artiva Biotherapeutics, Inc. does
Artiva Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ARTV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$83.9M | -$3.43 | -$79.3M |
| 2024 | $251K | -$65.4M | -$5.81 | -$55.7M |
| 2024 | $33.5M | -$28.7M | -$35.78 | -$50.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Artiva Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Restructuring or layoffs 8-K/A
- November 9, 2026
- October 27, 2026
- September 11, 2026
- September 11, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- August 6, 2026
Insider trades
What the people running Artiva Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.3M worth of shares in the last 90 days and bought none on the open market. 23% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Aslan FredChief Executive Officer, Director | Sold | 62,178 | $260K |
| November 2, 2026 | Banerjee SubhashisChief Medical Officer | Sold | 1,110 | $4.6K |
| November 2, 2026 | Bush JenniferCOO, CLO, Compliance Officer | Sold | 8,439 | $35.3K |
| November 2, 2026 | Horan ChristopherChief Tech Operations Officer | Sold | 10,423 | $43.6K |
| October 6, 2026 | Aslan FredChief Executive Officer, Director | Soldpre-planned (10b5-1) | 23,463 | $168.9K |
| October 5, 2026 | Aslan FredChief Executive Officer, Director | Sold | 61,696 | $421.8K |
| October 5, 2026 | Banerjee SubhashisChief Medical Officer | Sold | 1,099 | $7.5K |
| October 5, 2026 | Bush JenniferCOO, CLO, Compliance Officer | Sold | 8,370 | $57.2K |
Who owns ARTV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 37.9% | July 23, 2026 |
| GC Corp13D, may seek influence with 2 related filers | 12.3% | May 28, 2026 |
| Viking Global Investors LP13G, passive with 9 related filers | 5.4% | May 18, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 72 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 17,955,642 | +8,102,340 |
| Viking Global Investors LP | 2,604,166 | new |
| Blackstone Inc. | 2,403,437 | new |
| 5AM Venture Management, LLC | 2,353,304 | 0 |
| Venrock Adviser, LLC | 2,043,596 | +434,027 |
| Franklin Resources Inc | 1,997,223 | +1,476,896 |
| Caligan Partners LP | 1,736,111 | new |
| Vanguard Capital Management LLC | 981,815 | +774,129 |
| Samsara Biocapital, LLC | 954,861 | new |
| Blue Owl Capital Holdings LP | 874,542 | new |
| Propel Bio Management, LLC | 696,436 | +550,067 |
| BlackRock, Inc. | 694,726 | +481,338 |
| Citadel Advisors LLC | 609,376 | +593,506 |
| Nantahala Capital Management, LLC | 600,000 | new |
| Silverarc Capital Management, LLC | 525,000 | new |
| Geode Capital Management, LLC | 353,845 | +252,150 |
| Boothbay Fund Management, LLC | 314,375 | new |
| Revelation Capital Management, LLC | 299,311 | 0 |
| Alyeska Investment Group, L.P. | 273,615 | +173,615 |
| Acuta Capital Partners, LLC | 260,416 | new |
Insiders
10 insiders reported holding 26,205,564 shares in total, about $106.4M at the last price.
| Holder | Shares |
|---|---|
| Ra Capital Management, L.P.Director, 10% owner | 17,329,57017,329,570 held indirectly |
| GC Corp.10% owner | 5,999,7031,607,734 held indirectly |
| Aslan FredChief Executive Officer, Director | 1,457,428 |
| Bush JenniferCOO, CLO, Compliance Officer | 357,720 |
| Horan ChristopherChief Tech Operations Officer | 302,321 |
| Huston Thad AllenChief Financial Officer | 220,000 |
| Banerjee SubhashisChief Medical Officer | 168,738 |
| Raymon HeatherSVP, Research and Development | 148,228 |
| Miralles Gines DiegoPresident & Head of R&D | 122,500 |
| Krishnamohan NehaChief Financial Officer | 99,356 |
Questions about ARTV
What does Artiva Biotherapeutics, Inc. do?
Artiva Biotherapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ARTV. Its shares trade on NASDAQ under the ticker ARTV.
What is Artiva Biotherapeutics, Inc.'s net worth?
Artiva Biotherapeutics, Inc. has a market value (market cap) of $198.5M at the latest share price, and shareholders' equity of $320.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Artiva Biotherapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $98.1M.
When did Artiva Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Artiva Biotherapeutics, Inc.'s next earnings report?
Artiva Biotherapeutics, Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ARTV with
Follow ARTV
Get an email when Artiva Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Artiva Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.